Requirement of type III TGF-β receptor for endocardial cell transformation in the heart

Science

Volumn 283, Issue 5410, 1999, Pages 2080-2082

  Brown, Christopher B ^a   Boyer, Angelique S ^b   Runyan, Raymond B ^b   Barnett, Joey V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CHICK EMBRYO; CONTROLLED STUDY; EMBRYO; ENDOCARDIUM; ENDOTHELIUM CELL; EPITHELIUM CELL; HEART DEVELOPMENT; IMMUNOHISTOCHEMISTRY; MESENCHYME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CELL MOVEMENT; CHICK EMBRYO; CULTURE TECHNIQUES; ENDOCARDIUM; ENDOTHELIUM; GENETIC VECTORS; HEART; HEART ATRIA; HEART VENTRICLES; IMMUNE SERA; LIGANDS; MESODERM; MYOCARDIUM; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETROVIRIDAE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0033605704     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5410.2080     Document Type: Article

References (36)

1. A. B. Roberts and M. B. Sporn, in Peptide Growth Factors and their Receptors, M. B. Sporn and A. B. Roberts, Eds. (Springer-Verlag, New York, 1990), vol. 1, pp. 419-472.
2. J. L. Wrana, L. Attisano, R. Wieser, F. Ventura, J. Massague, Nature 370, 341 (1994); C. H. Bassing et al., Science 263, 87 (1994).
3. J. L. Wrana, L. Attisano, R. Wieser, F. Ventura, J. Massague, Nature 370, 341 (1994); C. H. Bassing et al., Science 263, 87 (1994).
4. M. Kretzschmar and J. Massague, Curr. Opin. Genet. Dev. 8, 103 (1998).
5. F. Lopez-Casillas, J. L. Wrana, J. Massague, Cell 73, 1435 (1993).
6. F. Lopez-Casillas et al., ibid. 67, 785 (1991); X.-F. Wang et al., ibid., p. 797.
7. F. Lopez-Casillas et al., ibid. 67, 785 (1991); X.-F. Wang et al., ibid., p. 797.
8. R. B. Runyan and R. R. Markwald, Dev. Biol. 95, 108 (1983).
9. L. M. Eisenberg and R. R. Markwald, Circ. Res. 77, 1 (1995); M. C. Fishman and K. R. Chien, Development 124, 2099 (1997).
10. L. M. Eisenberg and R. R. Markwald, Circ. Res. 77, 1 (1995); M. C. Fishman and K. R. Chien, Development 124, 2099 (1997).
11. J. D. Potts and R. B. Runyan, Dev. Biol. 134, 392 (1989).
12. C. B. Brown, A. S. Boyer, R. B. Runyan, J. V. Barnett, ibid. 174, 248 (1996).
13. 125I-TGF-β1 (NEN-DuPont) as described previously (17) after incubation with PI or I antisera (5 to 60 μg/ml). Specific binding was determined by the addition of 500 pM TGF-β1 or TGF-β2. Equal volumes of cell lysates were added per gel lane for cross-linking experiments or per sample for immunoprecipitation studies. For cross-linking experiments, the resultant banding patterns were examined by autoradiography and quantified by Phosphorimage analysis. Preimmune antisera had no effect on ligand binding.
14. A. Moustakas et al., J. Biol. Chem. 268, 22215 (1993); S. Sankar, N. Mahooti-Brooks, M. Centrella, T. L. McCarthy, J. A. Madri, ibid. 270, 13567 (1995).
15. A. Moustakas et al., J. Biol. Chem. 268, 22215 (1993); S. Sankar, N. Mahooti-Brooks, M. Centrella, T. L. McCarthy, J. A. Madri, ibid. 270, 13567 (1995).
16. C. B. Brown and J. V. Barnett, unpublished data.
17. Supplementary material is available at http://www. sciencemag.org/feature/data/985904.shl.
18. 9 plaque-forming units per milliliter) (24) and placed on collagen gels. After 12 hours vehicle or 200 pM TGF-β2 was added and each explant analyzed as above after 24 hours. Cells were identified as virally infected by AMV3C2 antibody staining or alkaline phosphatase activity (25). The number of infected mesenchymal cells was divided by the total number of infected cells. All mean comparisons by Student's t test.
19. Ventricular explants were assayed for mesenchyme production, and no significant difference was noted between groups. The number of explants examined were as follows: vehicle addition (n = 26), TGF-β1 (n = 19), and TGF-β2 (n = 22).
20. F. Lopez-Casillas, H. M. Payne, J. L. Andres, J. Massague, J. Cell Biol. 124, 557 (1994); H .Y. Lin et al., J. Biol. Chem. 270, 2747 (1995).
21. F. Lopez-Casillas, H. M. Payne, J. L. Andres, J. Massague, J. Cell Biol. 124, 557 (1994); H .Y. Lin et al., J. Biol. Chem. 270, 2747 (1995).
22. M. C. Dickson, H. G. Slager, E. Duffie, C. L. Mummery, R. J. Akhurst, Development 117, 625 (1993); J. V. Barnett et al., Dev. Dyn. 199, 12 (1994).
23. M. C. Dickson, H. G. Slager, E. Duffie, C. L. Mummery, R. J. Akhurst, Development 117, 625 (1993); J. V. Barnett et al., Dev. Dyn. 199, 12 (1994).
24. L. P. Sanford et al., Development 124, 2659 (1997).
25. M. M. Shull et al., Nature 359, 693 (1992); A. B. Kulkarni et al., Proc. Natl. Acad. Sci. U.S.A. 90, 770 (1993); G. Proetzel et al., Nature Genet. 11, 409 (1995).
26. M. M. Shull et al., Nature 359, 693 (1992); A. B. Kulkarni et al., Proc. Natl. Acad. Sci. U.S.A. 90, 770 (1993); G. Proetzel et al., Nature Genet. 11, 409 (1995).
27. M. M. Shull et al., Nature 359, 693 (1992); A. B. Kulkarni et al., Proc. Natl. Acad. Sci. U.S.A. 90, 770 (1993); G. Proetzel et al., Nature Genet. 11, 409 (1995).
28. M. H. Lakkis and J. A. Epstein, Development 125, 4359 (1998).
29. J. L. de la Pompa et al., Nature 392, 182 (1998); A. M. Ranger et al., ibid., p. 186.
30. J. L. de la Pompa et al., Nature 392, 182 (1998); A. M. Ranger et al., ibid., p. 186.
31. D. W. Johnson, M. Qumsiyeh, M. Benkhalifa, D. A. Marchuk, Genomics 28, 356 (1995); V. C. Sheffield et al., Hum. Mol. Genet. 6, 117 (1997).
32. D. W. Johnson, M. Qumsiyeh, M. Benkhalifa, D. A. Marchuk, Genomics 28, 356 (1995); V. C. Sheffield et al., Hum. Mol. Genet. 6, 117 (1997).
33. V. Hamburger and H. L. Hamilton, J. Morphol. 88, 49 (1951).
34. B. A. Morgan and D. M. Fekete, Methods Cell Biol. 51, 185 (1996).
35. W. M. Potts, M. Olsen, D. Boettiger, V. Vogt, J. Gen. Virol. 68, 3177 (1987); supplied by the Developmental Studies Hybridoma Bank, University of Iowa.
36. We thank R. Emeson, A. George, L. Limbird, B. Hogan, C. Wright, and members of the Barnett laboratory for critical reading of the manuscript, M. Cleggett for technical assistance, C. Cepko for RCASBP containing alkaline phosphatase, and H. Moses for thoughtful discussion. Supported by grants HL52922 (J.V.B.), 38649 (R.B.R.), 42266 (R.B.R.), and FY98-0446 from the March of Dimes Birth Defects Foundation (J.V.B.), C.B.B. was supported by an institutional training grant from the NIH General Medical Sciences number GM07628. J.V.B. and R.B.R. are Established Investigators of the American Heart Association. J.V.B. wishes to acknowledge the support of the Vanderbilt Cancer Center, NCI CA68485.